Elicio Therapeutics Other Operating Expenses Over Time
| ELTX Stock | 4.88 0.20 3.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Elicio Therapeutics Performance and Elicio Therapeutics Correlation. Elicio |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elicio Therapeutics. If investors know Elicio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elicio Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.44) | Return On Assets (0.97) | Return On Equity (3.53) |
The market value of Elicio Therapeutics is measured differently than its book value, which is the value of Elicio that is recorded on the company's balance sheet. Investors also form their own opinion of Elicio Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Elicio Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elicio Therapeutics' market value can be influenced by many factors that don't directly affect Elicio Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elicio Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Elicio Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elicio Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Operating Expenses Analysis
Compare Elicio Therapeutics and related stocks such as Oric Pharmaceuticals, Lyra Therapeutics, and Inhibrx Other Operating Expenses Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORIC | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 28.6 M | 49.3 M | 78.9 M | 86.8 M | 110.8 M | 69.1 M |
| LYRA | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 16.5 M | 22.2 M | 43.9 M | 56.4 M | 68.7 M | 39.6 M |
| INBX | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 37 M | 52.8 M | 80.3 M | 83.7 M | 131.3 M | 221 M | 232.1 M |
| EPIX | 0.0 | 0.0 | 0.0 | 1.7 M | 9.2 M | 18.7 M | 10.9 M | 10.8 M | 12.2 M | 23.5 M | 37.1 M | 37 M | 32.1 M | 37 M | 19.3 M |
| SNSE | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.4 M | 18.7 M | 37.5 M | 50.2 M | 37.1 M | 30.9 M |
| NXTC | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 23.2 M | 43.8 M | 63.6 M | 70.8 M | 75.9 M | 67.6 M | 56.6 M |
| NUVB | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 43.6 M | 93.3 M | 119.7 M | 99.8 M | 85.5 M |
| GLUE | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 28 M | 72.9 M | 112.4 M | 143.3 M | 80.2 M |
| ERAS | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | 37.5 M | 96.5 M | 145.4 M | 141.5 M | 95.5 M |
Elicio Therapeutics and related stocks such as Oric Pharmaceuticals, Lyra Therapeutics, and Inhibrx Other Operating Expenses description
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Elicio Therapeutics. It is also known as Elicio Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.My Equities
My Current Equities and Potential Positions
| Elicio Therapeutics | ELTX |
| Classification | Pharmaceutical Products |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
null 4.88
Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.